Marcus Yountz

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett et al. · Annals of Neurology · 2023 · 191 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 <scp>IgG‐Positive NMOSD</scp>

Dean M. Wingerchuk, Kazuo Fujihara, Jacqueline Palace et al. · Annals of Neurology · 2021 · 96 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace et al. · Multiple Sclerosis Journal · 2021 · 78 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses

James F. Howard, Chafic Karam, Marcus Yountz et al. · Annals of Clinical and Translational Neurology · 2021 · 62 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 40 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15